TrialRMD open2024

Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study.

Roy Fleischmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.